Breathe Well Live Well
Condition: Asthma
Interventions: Drug: dupilumab SAR231893 (REGN668); Drug: Placebo; Drug: Asthma Reliever Therapies; Drug: Asthma Controller Therapies (Incl. prednisone/prednisolone)
Sponsors: Sanofi; Regeneron Pharmaceuticals
Not yet recruiting – verified October 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
| Related Articles |
Exposure to Community Violence and Physical Health Outcomes in Youth: A Systematic Review.
J Pediatr Psychol. 2016 Oct 28;:
Authors: Wright AW, Austin M, Booth C, Kliewer W
Abstract
OBJECTIVE?: To systematically review the evidence for associations between exposure to community violence and physical health outcomes in children and adolescents. METHODS?: A thorough search of multiple online databases and careful consideration of inclusion and exclusion criteria yielded a final 28 studies for detailed review. In addition to review of findings, studies were rated on overall quality based on study design. RESULTS?: Seven categories of physical health outcomes emerged, including asthma/respiratory health, cardiovascular health, immune functioning, hypothalamic-pituitary-adrenal axis functioning, sleep problems, weight, and a general health category. There were mixed findings across these categories. Evidence for a positive association between community violence exposure and health problems was strongest in the cardiovascular health and sleep categories. CONCLUSION?: There is reason to believe that community violence exposure has an effect on some areas of physical health. Additional well-designed research that focuses on mechanisms as well as outcomes is warranted.
PMID: 27794530 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Condition: Asthmatic Attack
Interventions: Behavioral: Interactive Asthma Education; Behavioral: Standard Asthma Education
Sponsor: Ann & Robert H Lurie Children’s Hospital of Chicago
Recruiting – verified October 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Intervention: Drug: L-Citrulline
Sponsor: University of Colorado, Denver
Not yet recruiting – verified October 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Interventions: Drug: Reslizumab; Drug: Fludeoxyglucose F 18 (FDG); Drug: Placebo
Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Not yet recruiting – verified October 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Bronchial Asthma
Interventions: Drug: Ke Chuan Liu Wei Mixture; Drug: Chuan Xiong Ping Chuan Mixture; Drug: Xie Wu Capsule; Drug: Dan Ma Jia Tablet; Drug: Zhi Chuan Capsule; Drug: Bu Shen Na Qi Granule; Drug: Ke Chuan Liu Wei Mixture placebo; Drug: Chuan Xiong Ping Chuan Mixture placebo; Drug: Xie Wu Capsule placebo; Drug: Dan Ma Jia Tablet placebo; Drug: Zhi Chuan Capsule placebo; Drug: Bu Shen Na Qi Granule placebo
Sponsor: Shanghai University of Traditional Chinese Medicine
Not yet recruiting – verified October 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
 |
Related Articles |
Th1/Th2 Immune Balance and Other T Helper Subsets in IgG4-Related Disease.
Curr Top Microbiol Immunol. 2016 Oct 16;
Authors: Moriyama M, Nakamura S
Abstract
IgG4-related disease (IgG4-RD) is a systemic disease characterized by elevated serum IgG4 levels and a strong infiltration of IgG4-positive plasma cells in various organs. IgG4-RD patients also frequently suffer from allergic diseases, including asthma and atopic dermatitis. It is well known that T helper type 2 (Th2) cells have an important role in the initiation of allergic diseases, and Th2 cytokines such as interleukin (IL)-4 and IL-13 promote class switching to IgG4. Therefore, IgG4-RD is considered to be a Th2-predominant disease. However, other Th subsets, including regulatory T cells and T follicular helper cells, have recently received increasing attention with regard to the pathogenesis of IgG4-RD. Exploring the interconnected network of Th subsets in IgG4-RD is a highly promising field of investigation. In this review, we focus on the localization and functions of individual Th subsets to clarify the involvement of these cells in the pathogenesis of IgG4-RD.
PMID: 27744510 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Condition: Bronchial Asthma
Intervention: Drug: budesonide 160?g/formoterol 4.5?g
Sponsor: Zhujiang Hospital
Recruiting – verified July 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Treatment A – AZD7594; Drug: Treatment B – AZD7594; Drug: Treatment C – AZD7594
Sponsor: AstraZeneca
Not yet recruiting – verified October 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: Treatment A – AZD7594; Drug: Treatment B – AZD7594; Drug: Treatment C – AZD7594
Sponsor: AstraZeneca
Not yet recruiting – verified October 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days